EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
JJ Kang, A Ko, SH Kil, JMS Clair, DS Shin… - … et Biophysica Acta (BBA …, 2023 - Elsevier
Receptor tyrosine kinases (RTKs) are cell surface receptors that bind growth factor ligands
and initiate cellular signaling. Of the 20 classes of RTKs, 7 classes, IV, VIII, and X, are linked …
and initiate cellular signaling. Of the 20 classes of RTKs, 7 classes, IV, VIII, and X, are linked …
Treatment outcome under cetuximab-based therapy and individual ADCC capability in head and neck cancer
C Lo Nigro, L Lattanzio, D Vivenza, M Monteverde… - Cancer Research, 2016 - AACR
Abstract Introduction Cetuximab is a IgG1 monoclonal antibody against epidermal growth
factor receptor (EGFR) used for head and neck squamous cell carcinoma (HNSCC) …
factor receptor (EGFR) used for head and neck squamous cell carcinoma (HNSCC) …
[HTML][HTML] Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma
Cetuximab, an EGFR-blocking antibody, is currently approved for treatment of metastatic
head and neck squamous cell carcinoma (HNSCC), but its response rate is limited. In …
head and neck squamous cell carcinoma (HNSCC), but its response rate is limited. In …
Head and neck cancer: The role of anti-EGFR agents in the era of immunotherapy
M Fasano, CM Della Corte, G Viscardi… - … in medical oncology, 2021 - journals.sagepub.com
Head and neck cancers (HNC) represent the seventh most frequent cancer worldwide, with
squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for …
squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for …
Multi-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma
Background Head and neck squamous cell carcinoma (HNSCC) is a debilitating disease
with poor survival rates. While the epidermal growth factor receptor (EGFR)-targeting …
with poor survival rates. While the epidermal growth factor receptor (EGFR)-targeting …
Novel, rationally designed combination strategies, based on (phospho) proteomic analyses, to enhance the response to cetuximab therapy in head and neck cancer
H Zaryouh - 2024 - repository.uantwerpen.be
Head and neck squamous cell carcinoma (HNSCC) arises from the mucosal epithelium of
different anatomical subsites in the head and neck regions, including the oral cavity …
different anatomical subsites in the head and neck regions, including the oral cavity …
[PDF][PDF] Immune modulatory effects of lapatinib and erlotinib on EGFR-associated pathways in head and neck squamous cell carcinoma
B Yang - 2023 - opendata.uni-halle.de
The treatment of patients with head and neck squamous cell carcinoma (HNSCC) is
extraordinarily complex and challenging, and despite the availability of novel targeted drugs …
extraordinarily complex and challenging, and despite the availability of novel targeted drugs …
[HTML][HTML] Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab
Abstract The Epidermal Growth Factor Receptor (EGFR) is selectively expressed on the
surface of numerous tumours, such as non-small cell lung, ovarian, colorectal and head and …
surface of numerous tumours, such as non-small cell lung, ovarian, colorectal and head and …
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen–specific T-cell immunity in head and neck cancer patients
RM Srivastava, SC Lee, PA Andrade Filho… - Clinical Cancer …, 2013 - AACR
Purpose: Tumor antigen–specific monoclonal antibodies (mAb) block oncogenic signaling
and induce Fcγ receptor (FcγR)–mediated cytotoxicity. However, the role of CD8+ CTL and …
and induce Fcγ receptor (FcγR)–mediated cytotoxicity. However, the role of CD8+ CTL and …